Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.

Enabling independent CytoSorb® Therapy

*Not available for human use in the USA

 

CE-marked under MDR since 06/2024

Provide hemoadsorption therapy when CytoSorbents therapies are required.

 

PuriFi is designed for the standalone application of CytoSorb®, enabling straightforward setup and familiar handling for extracorporeal circuit trained personnel. With its compact and mobile design, PuriFi can be used in the Emergency Room, Intensive Care Unit, or Intermediate Care settings.

PuriFi Features

Intuitive touchscreen interface
Maintenance-free pressure monitoring
Pre-assembled adult and pediatric line kit
Auto-leveling bubble catcher
Temperature management option
Setup in approx. 10 minutes including automated adsorber priming

Engineered for independent application of CytoSorb® as stand-alone system

Extensive clinical experience

With more than 300,000 hemoadsorption treatments performed worldwide over the past ten years, CytoSorb® technology has been extensively used in clinical practice and continuously monitored for safety and performance.

 

Over 1,100 scientific contributions

CytoSorbents’ hemoadsorption technology is supported by a large and growing body of peer-reviewed literature and clinical evidence.

Clinical experience across multiple indications

Research and clinical use of CytoSorbents’ hemoadsorption therapies have been reported in cardiovascular, renal, hepatic, and critical-care settings.

Contact us to discover more
about PuriFi

PuriFi at a glance

  • Mitzner et al. J Clin Med. 2023;12(23):7199
  • Schmoeckel et al., J Throm & Thrombolysis 2024; epub
  • Doukas et al., J Clin Med 2023; 12:546
  • Haidari et al., ICV&TS 2023; 36(1):ivad010
  • Nemeth et al., ESC Heart Failure 2024; 11(2):772-782
  • Grafe et al., Ren Fail 2023; 45(2):2259231
  • Haselwanter et al., Sci Rep 2024; 14(1):11309
  • Jansen et al., Critical Care 2023; 27(1):117
  • Akil et al., J Clin Med 2022; 11(20):5990

 
PuriFi IFU Intended Use (07/2025):
PuriFi is indicated when a hemoperfusion procedure is prescribed by a physician and provides the required system environment of the prescribed adsorption column. The system environment includes equipment (PuriFi) used to drive, control, and monitor extracorporeal blood circulation, the tube set, and associated accessories such as vascular access devices and their interconnections. When used together with CytoSorbents’ wholeblood adsorption columns (Device), the system is intended to remove specific molecules as specified in the adsorption columns’ Instructions for Use.

CytoSorbents

Voices around the world

world map
Critical Care
Dr. Giorgio Berlot
Trieste, Italy

Treat the patient as soon as possible within 48 hours and as much as possible. The more and earlier you treat, the better the outcome of the patient.

About CytoSorbents
Prof. Jean Louis Vincent
Brussels, Belgium

I would like to send my congratulations on the 10th anniversary of CytoSorb®. It is great how you have created a new way of blood purification therapy.

Cardiovascular
Dr. Helmut Mair
Munich, Germany

We had no bleeding problems whatsoever. The adsorber was in use throughout the operation. It worked really well. We believe in this product.